

COVID – 19

You can find a dedicated section on the [APC website](#) for use during the COVID crisis.

According to Roche, their new COVID-19 antibody test has “a specificity greater than 99.8% and a sensitivity of 100%.” - Find out what this means [here](#)

New Submissions July 2020

Utrogestan® (Micronised progesterone)	GREEN	Gynaecology	As a 2nd line option for patients requiring combined HRT but unsuitable or intolerant of standard combination preparations. These include women at high risk of VTE (e.g. migraines, BMI >30, PMH of VTE) where transdermal oestrogen is preferred but in whom Evorel Conti is not tolerated or unsuitable because of the need for variable oestrogen dose.
Methylphenidate and dexamfetamine	AMBER 1	Narcolepsy	Not to be added to the formulary until shared care guidance is developed and approved.
Humalog® 200 (insulin lispro 200 units/ml)	AMBER 2	Diabetes	For patients who require higher doses of insulin due to insulin resistance.
Isocarboxazid	AMBER 2	Major depressive disorder	Major Depressive Disorder – Persistent and Treatment Resistant without Bipolarity. In place of phenelzine which is no longer available.

News from the APC - updated/new documents on the APC website:

- [APC annual report 201920](#)
- [Nausea and vomiting in pregnancy](#) (Update)
- [Type 2 diabetes guideline](#) (Update) - no change to treatment algorithm
- [Heart failure guideline](#) (Update)
- [Dementia Medication Information Sheets](#) (Update)
- [Stoma Ancillary Items Formulary](#) (Update)
- [Management of Psoriasis \(Adults & Children\) in Primary Care](#) (New Guideline)
- [Rheumatological conditions SCP and information sheets](#) (Update) - no change to monitoring schedules.
- [Alcohol Dependence Guideline](#) (Update to vitamin B section only)
- Coming in the next two weeks - Phosphate binders SCP (Update), Antimicrobial guideline – Diabetic foot (Update)

The combined antimicrobial PDF has now been retired. Use the search function on the website to find the required section of the guideline.

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments:

- Slow K® – **GREY** (Discontinued)
- Colifoam® – **GREY** (Discontinued) Budesonide now first choice rectal foam.
- Zonisamide – The restriction for the dose to be stable before transfer is to be removed for adults. Clear direction for GP to manage titrating dose will be given by the specialist.
- Aymes Shake Compact® – **AMBER 3** pending ONS guideline update, **AMBER 2** in the interim
- Evolve HA® eye lubricant – **GREEN** and to be added to the eye lubricant guideline
- Systane® Ultra & Optive Plus eye lubricants – **GREY** (no longer a cost effective option)
- Danazol – **RED** for existing patients if alternative not suitable. Existing patients to obtain prescriptions from the GP until reviewed by specialist
- Levetiracetam – Restriction on who can initiate and the information about the liquid cost to be removed.

Horizon scanning:

- Ritalin XL® – **GREY** no advantage over current formulary options
- Lenzetto® transdermal spray (estradiol) – **GREY** no formal assessment
- Oxycodone/naloxone (Myloxifin®) – **GREY**
- Epiduo 0.3% – **GREEN** for severe acne with self care remaining first line.
- Peppermint oil (Buscomint®) – **GREY** no formal assessment (review again when price available)
- Amoxicillin 1g dispersible tablets – **GREY** more expensive than suspension.
- Apremilast (Otezla®) – Deferred to trust DTCs for consideration for **RED**
- Budesonide orodisp (Jorvesa) – Deferred to trust DTCs for consideration for **RED**
- Semaglutide (Rybelsus®) – **GREY** no formal assessment (Oral GLP1 agonist)
- Trifarotene cream (Aklief®) – **GREY** no formal assessment
- Lyumjev® (insulin lispro rapid acting) – **GREY** no formal assessment (prescribe Lispro products by brand, NOT interchangeable)

Current work in development

- Aminosalicylates in Inflammatory Bowel Disease in Adults
- Testosterone information sheet
- Bowen's Disease Primary Care Treatment Pathway
- Autoimmune hepatitis SCP and information sheet
- Omeprazole liquid review process
- COPD Guideline
- Asthma in adults guideline
- Opioids for persistent non cancer pain
- SIP feed guidelines update
- Specials database
- Antidepressants in Primary Care
- Sleep and melatonin guidance

Upcoming NICE publications

Title	Type	Anticipated publication date
Insect bites and stings antimicrobial prescribing	Guidance	December 2019 – delayed TBC
Human and Animal bites: antimicrobial prescribing	Guidance	June 2020 – delayed to November 2020
Naldemedine for opioid induced constipation	TA	Delayed - TBC
Acute Coronary Syndrome	Guidance	Delayed TBC
Low back pain and sciatica in over 16s: targeted review of pharmacological interventions	Guidance	September 2020

The work of the NAPC is supported and managed by the interface team below. They can be contacted via MACCG.NottsAPC@nhs.net

Laura Catt (LC), Prescribing Interface Advisor, Nottingham and Nottinghamshire CCG

Karen Robinson (KR), Interface and APC Technician, Nottingham and Nottinghamshire CCG

Lynne Kennell (LK), Specialist Interface and formulary pharmacist, Sherwood Forest Hospital.

Shary Walker (SW), Specialist Interface and Formulary Pharmacist NUH

Jill Theobald (JT) Specialist Interface Efficiencies Pharmacist, Nottingham and Nottinghamshire CCG

Irina Varlan (IV) Specialist Interface Efficiencies Pharmacist, Nottingham and Nottinghamshire CCG

Hannah Godden (HG) Specialist Mental Health Efficiencies Pharmacist, Nottinghamshire Healthcare Trust